Published in J Virol on October 13, 2010
IFITM3 restricts the morbidity and mortality associated with influenza. Nature (2012) 4.66
Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 3.44
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80
Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol (2012) 2.21
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun (2013) 2.00
Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog (2012) 1.97
IFITM proteins restrict viral membrane hemifusion. PLoS Pathog (2013) 1.86
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 1.86
S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem (2012) 1.67
The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol (2012) 1.64
Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog (2012) 1.60
Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 1.56
The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol (2013) 1.54
IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol (2013) 1.52
Enhanced survival of lung tissue-resident memory CD8⁺ T cells during infection with influenza virus due to selective expression of IFITM3. Nat Immunol (2013) 1.45
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio (2011) 1.30
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
Mechanism of HIV-1 virion entrapment by tetherin. PLoS Pathog (2013) 1.24
Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol (2014) 1.23
Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev (2011) 1.22
Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog (2013) 1.21
SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog (2011) 1.20
How SAMHD1 changes our view of viral restriction. Trends Immunol (2011) 1.15
Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem (2013) 1.15
Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol (2012) 1.14
Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses (2011) 1.13
Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS One (2012) 1.13
Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem (2013) 1.11
Counteraction of the multifunctional restriction factor tetherin. Front Microbiol (2014) 1.09
IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. Annu Rev Virol (2014) 1.08
Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology (2011) 1.08
Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep (2013) 1.08
β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology (2011) 1.07
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A (2014) 1.04
Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity. J Virol (2013) 1.03
Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem (2014) 1.00
Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression. J Virol (2011) 0.99
IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. Cell Rep (2015) 0.98
Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection. J Immunol (2012) 0.97
Long Non-Coding RNA BST2/BISPR is Induced by IFN and Regulates the Expression of the Antiviral Factor Tetherin. Front Immunol (2015) 0.96
Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One (2013) 0.95
Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines. Viruses (2013) 0.95
The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. J Virol (2015) 0.94
Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis (2011) 0.92
Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS (2015) 0.91
Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell model. J Gen Virol (2013) 0.91
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. J Biol Chem (2015) 0.90
Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J Virol (2013) 0.90
Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology (2014) 0.89
HIV-1 mutates to evade IFITM1 restriction. Virology (2014) 0.89
Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol (2011) 0.89
Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism. Front Microbiol (2011) 0.89
E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3. PLoS Pathog (2015) 0.88
Influenza A virus-induced degradation of eukaryotic translation initiation factor 4B contributes to viral replication by suppressing IFITM3 protein expression. J Virol (2014) 0.88
Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment. J Virol (2014) 0.88
Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3. Sci Rep (2016) 0.87
Vpu and BST2: Still Not There Yet? Front Microbiol (2012) 0.87
A functional promoter polymorphism of IFITM3 is associated with susceptibility to pediatric tuberculosis in Han Chinese population. PLoS One (2013) 0.85
The presence of the iron-sulfur motif is important for the conformational stability of the antiviral protein, Viperin. PLoS One (2012) 0.85
Interferon-Inducible Transmembrane Protein 3 Genetic Variant rs12252 and Influenza Susceptibility and Severity: A Meta-Analysis. PLoS One (2015) 0.85
Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation. J Biol Chem (2013) 0.84
Antagonism to human BST-2/tetherin by Sendai virus glycoproteins. J Gen Virol (2013) 0.84
The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis. J Virol (2016) 0.83
Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol (2014) 0.83
A sorting signal suppresses IFITM1 restriction of viral entry. J Biol Chem (2014) 0.83
The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses. J Virol (2016) 0.82
The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation. J Virol (2014) 0.82
BST2/tetherin inhibits dengue virus release from human hepatoma cells. PLoS One (2012) 0.82
Tetherin upregulation in simian immunodeficiency virus-infected macaques. J Virol (2013) 0.82
Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo. J Mol Biol (2013) 0.82
IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. Sci Rep (2012) 0.82
The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PLoS One (2015) 0.81
Cellular restriction factors of feline immunodeficiency virus. Viruses (2011) 0.81
Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation. J Biol Chem (2013) 0.81
Cellular Antiviral Factors that Target Particle Infectivity of HIV-1. Curr HIV Res (2016) 0.80
Identification and functional analysis of three isoforms of bovine BST-2. PLoS One (2012) 0.80
Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses an Early Infection Block to Human Influenza Viruses. J Virol (2016) 0.79
Early Vertebrate Evolution of the Host Restriction Factor Tetherin. J Virol (2015) 0.79
Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses. J Gen Virol (2015) 0.79
IFITMs from Mycobacteria Confer Resistance to Influenza Virus When Expressed in Human Cells. Viruses (2015) 0.79
Duck Interferon-Inducible Transmembrane Protein 3 Mediates Restriction of Influenza Viruses. J Virol (2015) 0.79
Widespread but tissue-specific patterns of interferon-induced transmembrane protein 3 (IFITM3, FRAGILIS, MIL-1) in the mouse gastrula. Gene Expr Patterns (2013) 0.79
Host restriction factors for hepatitis C virus. World J Gastroenterol (2016) 0.78
Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV. PLoS One (2016) 0.78
Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication. J Virol (2014) 0.78
Lipid interactions during virus entry and infection. Cell Microbiol (2014) 0.78
Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses. Viruses (2015) 0.78
Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. J Immunol Res (2017) 0.78
Therapeutic Targets for Neurodevelopmental Disorders Emerging from Animal Models with Perinatal Immune Activation. Int J Mol Sci (2015) 0.77
BST2/tetherin inhibition of alphavirus exit. Viruses (2015) 0.77
Bst2/Tetherin Is Induced in Neurons by Type I Interferon and Viral Infection but Is Dispensable for Protection against Neurotropic Viral Challenge. J Virol (2015) 0.77
CD317 Promotes the survival of cancer cells through apoptosis-inducing factor. J Exp Clin Cancer Res (2016) 0.77
A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. Traffic (2016) 0.77
Tetherin Antagonism by HIV-1 Group M Nef Proteins. J Virol (2016) 0.76
Pathogen recognition and innate immunity. Cell (2006) 44.14
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol (2007) 8.98
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Viruses and interferons. Annu Rev Microbiol (2001) 7.12
Innate recognition of viruses. Immunity (2007) 6.21
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell (2009) 5.06
Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol (2008) 4.72
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
MDA5/RIG-I and virus recognition. Curr Opin Immunol (2008) 4.05
Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98
Antiviral signaling through pattern recognition receptors. J Biochem (2006) 3.84
Ligand-induced redistribution of a human KDEL receptor from the Golgi complex to the endoplasmic reticulum. Cell (1992) 3.82
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology (1999) 3.44
The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol (2002) 3.22
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity (2000) 3.07
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
West Nile virus inhibits the signal transduction pathway of alpha interferon. J Virol (2005) 2.72
Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog (2009) 2.59
IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev Cell (2005) 2.57
Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol (2007) 2.46
Molecular analysis of a human interferon-inducible gene family. Eur J Biochem (1991) 2.46
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol (2007) 2.40
The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol (2000) 2.08
Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster. Mol Cell Biol (2008) 2.01
Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog (2010) 1.89
Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog (2010) 1.85
Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol (2008) 1.83
Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem (1995) 1.64
Rer1p, a retrieval receptor for ER membrane proteins, recognizes transmembrane domains in multiple modes. Mol Biol Cell (2003) 1.48
Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res (2006) 1.44
ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem (2003) 1.43
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol (2006) 1.34
VSV replication in neurons is inhibited by type I IFN at multiple stages of infection. Virology (2005) 1.33
IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene (2006) 1.24
PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent. Viral Immunol (2002) 1.23
Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology (2009) 1.23
Interferon-mediated inhibition of virus penetration. Proc Natl Acad Sci U S A (1983) 1.19
The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett (2005) 1.07
Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines. Cell Mol Life Sci (2003) 1.05
Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol (2008) 1.05
The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. Virology (2005) 1.01
Binding of IFITM1 enhances the inhibiting effect of caveolin-1 on ERK activation. Acta Biochim Biophys Sin (Shanghai) (2009) 0.89
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol (2003) 4.06
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol (2007) 2.40
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol (2008) 1.96
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells. J Virol (2002) 1.93
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem (2004) 1.78
An Updating System for the Gridded Population Database of China Based on Remote Sensing, GIS and Spatial Database Technologies. Sensors (Basel) (2009) 1.63
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res (2013) 1.29
Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. J Virol (2002) 1.29
Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol (2008) 1.28
Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis (2007) 1.28
A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother (2007) 1.27
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog (2013) 1.22
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Antiviral effect of interferon lambda against West Nile virus. Antiviral Res (2009) 1.12
Evaluation of hyperspectral indices for chlorophyll-a concentration estimation in Tangxun Lake (Wuhan, China). Int J Environ Res Public Health (2010) 1.11
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res (2012) 1.10
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
Water deficits and heat shock effects on photosynthesis of a transgenic Arabidopsis thaliana constitutively expressing ABP9, a bZIP transcription factor. J Exp Bot (2008) 1.10
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res (2010) 1.09
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol (2010) 1.08
Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology (2010) 1.08
Pre-anthesis high-temperature acclimation alleviates damage to the flag leaf caused by post-anthesis heat stress in wheat. J Plant Physiol (2011) 1.06
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
Implications of high-temperature events and water deficits on protein profiles in wheat (Triticum aestivum L. cv. Vinjett) grain. Proteomics (2011) 1.05
Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci (2008) 1.05
Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes. J Virol (2007) 1.04
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother (2009) 1.04
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A (2014) 1.04
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol (2002) 1.03
A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics (2003) 1.03
Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother (2010) 1.03
Social isolation-induced aggression potentiates anxiety and depressive-like behavior in male mice subjected to unpredictable chronic mild stress. PLoS One (2011) 1.03
Calculating the burden of disease of avian-origin H7N9 infections in China. BMJ Open (2014) 1.00
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection. Antiviral Res (2011) 0.99
Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology (2002) 0.98
Fucosylated glycoproteins as markers of liver disease. Dis Markers (2008) 0.98
Waterlogging pretreatment during vegetative growth improves tolerance to waterlogging after anthesis in wheat. Plant Sci (2011) 0.97
Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci (2004) 0.97
Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells. J Virol (2003) 0.96
Glyco- and peptidomimetics from three-component Joullié-Ugi coupling show selective antiviral activity. J Am Chem Soc (2005) 0.95
Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area. World J Gastroenterol (2003) 0.94
A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol (2013) 0.93
Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One (2012) 0.92